SCHEMBL7792227

SCHEMBL7792227

COC(=O)Nc1nc2c(Cl)c(Cl)c(Cl)c(Cl)c2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 8/20 0.36
▸ CYP1A2 P05177 6/20 0.36
▸ HIF1A Q16665 5/20 0.36
▸ KDR P35968 4/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ABCC4 O15439 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ TUBB4A P04350 5/20 0.36
▸ TUBB P07437 5/20 0.36
▸ TUBA3C P0DPH7 5/20 0.36
▸ TUBA1B P68363 5/20 0.36
▸ TUBA4A P68366 5/20 0.36
▸ TUBB4B P68371 5/20 0.36
▸ TUBB3 Q13509 5/20 0.36
▸ TUBB2A Q13885 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7793945 0.85 KDR (0.38) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7793948 0.85 KDR (0.38) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7793917 0.75 CSNK2A1 (0.59) —
SCHEMBL7517663 0.74 MAPK1 (0.41) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7792996 0.74 CSNK2A2 (0.41) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7789092 0.74 MAPK1 (0.39) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7789099 0.74 KDR (0.39) LMNACYP1A2HIF1AKDRSMN1; SMN2
Hydrochloric Acid SCHEMBL7792147 0.73 MAPK1 (0.40) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL24093963 0.71 LMNA (0.45) LMNACYP1A2HIF1AKDRSMN1; SMN2
SCHEMBL7792153 0.71 MAPK1 (0.39) LMNACYP1A2HIF1AKDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010047021-A1 Cancer treatment THE PROCTER & GAMBLE COMPANY 2001-11-29 — — US disclosed
WO-2001083457-A2 BENZIMIDAZOLE-2-CARBAMATES AND THEIR USE IN CANCER TREATMENT THE PROCTER & GAMBLE COMPANY (US) 2001-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047021-A1 Cancer treatment MUSK, ALK, BCOR LMNA 2325/4885CYP1A2 326/4885HIF1A 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback